The Molecular Genetics Program conducts fundamental research on the etiology, progression, prevention, detection, and treatment of cancer. The scientific foci of the group are on DNA damage, DNA repair, gene regulation, hormonal responsiveness, viral carcinogenesis, and familial cancer gene identification.. The 31 member5 group has weekly data presentation meetings, mini-symposia, and annual poster sessions in addition to the weekly Cancer Center Grand Rounds, as forums for interaction. The Molecular Genetics Program is sub-divided into four focus groups: Genetic Instability, Gene Control, Molecular Virology, and Human Cancer Center Grand Rounds, as forums for interaction. The Molecular Virology and Human Cancer Genetics. Several major cancer research discoveries have been made in the previous funding interval in this Program. Important new strides have been made in defining how DNA damage is repaired. Insights from this are important in understanding how chromosomal instability permits cancers to diversity as part of their progression. The Molecular Genetics Program members have discovered cancers to diversity as part of their progression. The Molecular Genetics Program members have discovered new proteins (and their genes) that are critical to how nuclear hormone receptors function, and this is relevant to the hormonal dependence on breast and prostate cancer. Major progress has also been made in defining a novel pathway for altering gene expression by acetylation of transcription factors. Marked progress has been made in understanding the molecular basis for the persistence of hepatitis C virus, which is important to its causing hepatocellular carcinoma. Other program members are collaborating to examine breast and prostate cancers for mutations in the newly described nuclear hormone receptor mentioned above. Genetic linkage analysis of prostate cancer families is underway, and is integrated into an international consortium. The analysis of prostate cancer families is underway, and is integrated into an international consortium. The Molecular Genetics Program members have been successful in developing or participating in program project grants in gene therapy and DNA repair as a result of the fruitful scientific interaction fostered by this Program. Hence, both scientific collaborations and cancer research discoveries are facilitated by the existence of the Molecular Genetics Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014089-26
Application #
6457494
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1980-04-01
Project End
2005-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48

Showing the most recent 10 out of 842 publications